Form 4: Palatin Technologies Director Arlene Morris Reports Stock and Option Grants

Director Arlene Morris reports the acquisition of restricted share units and stock options in Palatin Technologies, following certification related to the company's 2011 Stock Incentive Plan.

Summary

• On July 15, 2024, Arlene Morris, a director of Palatin Technologies, reported the acquisition of 12,000 restricted share units and 17,000 stock options.
• The restricted share units were granted under the 2011 Stock Incentive Plan and each represents the right to receive one share of common stock.
• These units vest on June 4, 2025.
• The stock options have an exercise price of $1.83 and also vest on June 4, 2025, with vesting prorated if the director doesn't serve until June 30, 2025.
• The grants were subject to certification by the Chief Financial Officer regarding the increase in shares reserved under the 2011 Stock Incentive Plan, which was completed on July 15, 2024.
• Following these transactions, Morris beneficially owns 41,580 shares of common stock and 57,180 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock and option grants, which is a standard practice. There are no explicit positive or negative implications.

Positives

• The grant of restricted share units and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedules incentivize continued service and contribution to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the granted securities.

Industry Context

Stock option and restricted share unit grants are common practices in the pharmaceutical and biotechnology industries to incentivize and retain key personnel, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages in the biotech industry, often benchmarked against peer companies of similar size and stage of development.
• Vesting schedules, such as the one described, are typical for aligning executive incentives with long-term company performance.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options and restricted stock units as part of their executive compensation packages.

Stakeholder Impact

• The grants could have a minor dilutive effect on existing shareholders.
• The grants incentivize the director to work towards increasing shareholder value.

Key Dates